Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,800 | $67.12 | $120,814.20 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,412 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $66.540 to $67.490, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,590 | $65.98 | $170,893.38 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302,212 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $65.530 to $66.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 900 | $65.01 | $58,506.30 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304,802 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $64.455 to $65.340, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:02 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $63.03 | $18,907.50 |
DisclosureSEC source: 0001447362-20-000297 · wf-form4_160832530700817.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,702 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.000 to $63.055, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2020 Filed Jan 11, 2021 21:55 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GiftCommon Stock | 3,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000002 · wf-form5_161040210937227.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,149 Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 202 | $61.79 | $12,480.57 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,306,002 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $61.325 to $62.010, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,120 | $60.65 | $128,575.88 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,306,204 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $60.320 to $61.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,255 | $59.72 | $552,680.84 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308,324 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $59.190 to $60.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,423 | $58.69 | $200,902.72 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,317,579 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.120 to $59.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 21,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · derivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,450 Underlying: Common Stock · 21,450 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F11 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on December 10, 2021. F11 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 87,100 | $0.00 Strike: $59.16 | $0.00 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · derivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,100 Underlying: Common Stock · 87,100 shares Expires 2030-12-09 F9 · derivative.exercise_date: 25% of shares shall vest on December 10, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 14,300 | $59.02 | $844,000.30 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,002 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.230 to $59.225, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 700 | $57.14 | $39,999.40 |
DisclosureSEC source: 0001447362-20-000287 · wf-form4_160797268160615.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335,302 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.800 to $57.610, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,250 | $51.75 | $323,462.50 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,002 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.260 to $51.985, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,126 | $51.58 | $212,798.45 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,252 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.170 to $51.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,124 | $50.84 | $107,988.41 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346,378 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.170 to $51.165, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $50.88 | $5,088.00 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348,502 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,850 | $50.23 | $243,596.10 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348,602 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.870 to $50.715, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,300 | $49.49 | $64,333.10 |
DisclosureSEC source: 0001447362-20-000274 · wf-form4_160712103652308.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,452 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.860 to $49.825, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 506 | $47.85 | $24,212.10 |
DisclosureSEC source: 0001447362-20-000268 · wf-form4_160625265862994.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,752 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $47.59 to $48.41, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,744 | $47.14 | $129,352.16 |
DisclosureSEC source: 0001447362-20-000268 · wf-form4_160625265862994.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355,258 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $46.56 to $47.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $48.65 | $24,325.00 |
DisclosureSEC source: 0001447362-20-000268 · wf-form4_160625265862994.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358,002 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.50 to $48.94, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,144 | $47.96 | $150,786.24 |
DisclosureSEC source: 0001447362-20-000268 · wf-form4_160625265862994.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358,502 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.42 to $48.41, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 21:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $46.80 | $14,040.00 |
DisclosureSEC source: 0001447362-20-000268 · wf-form4_160625265862994.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,646 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.37 to $47.28, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 801 | $48.23 | $38,628.23 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,946 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $48.020 to $48.510, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,755 | $47.54 | $130,980.97 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,747 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $46.960 to $47.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,694 | $46.37 | $124,926.17 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $45.880 to $46.850, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 600 | $50.44 | $30,261.60 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368,196 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $50.010 to $50.990, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,200 | $49.17 | $59,005.20 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368,796 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.840 to $49.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,450 | $48.45 | $215,602.50 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,996 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.830 to $48.820, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,250 | $50.55 | $315,925.00 |
DisclosureSEC source: 0001447362-20-000263 · wf-form4_160574043533732.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,446 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.190 to $50.905, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 545 | $50.99 | $27,790.64 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,380,696 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $50.710 to $51.255, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,307 | $50.07 | $265,710.88 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,381,241 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $49.590 to $50.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $48.92 | $48,923.00 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,386,548 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $48.555 to $49.215, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $46.36 | $9,272.00 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387,548 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $45.910 to $46.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $45.00 | $13,499.10 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387,748 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $44.630 to $45.480, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $50.34 | $50,341.00 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388,048 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.220 to $50.570, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,887 | $49.60 | $93,589.54 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389,048 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.130 to $50.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,163 | $48.54 | $56,455.51 |
DisclosureSEC source: 0001447362-20-000259 · wf-form4_160521711400523.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390,935 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.100 to $49.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,049 | $52.18 | $106,925.02 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,392,098 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $51.765 to $52.570, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,201 | $51.51 | $216,389.31 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,394,147 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $50.760 to $51.735, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,450 | $50.20 | $122,992.45 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,398,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.700 to $50.610, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,800 | $49.29 | $187,313.40 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,798 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.640 to $49.620, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,150 | $47.81 | $198,390.75 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,598 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.515 to $48.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,100 | $46.96 | $98,611.80 |
DisclosureSEC source: 0001447362-20-000249 · wf-form4_160461724172055.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408,748 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.490 to $47.440, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 237 | $48.56 | $11,508.25 |
DisclosureSEC source: 0001447362-20-000247 · wf-form4_160408882247354.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,410,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $48.250 to $48.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 863 | $47.67 | $41,134.90 |
DisclosureSEC source: 0001447362-20-000247 · wf-form4_160408882247354.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,085 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.155 to $48.130, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $50.04 | $15,012.90 |
DisclosureSEC source: 0001447362-20-000247 · wf-form4_160408882247354.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,948 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.010 to $50.110, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 900 | $49.38 | $44,439.30 |
DisclosureSEC source: 0001447362-20-000247 · wf-form4_160408882247354.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412,248 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.010 to $49.680, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $48.87 | $48,869.00 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,148 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.400 to $49.085, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.